#1 Clinical Trials Search in Europe

Bupropion Hydrochloride

Bupropion Hydrochloride, a medication used primarily for depression and smoking cessation, has been the subject of several clinical trials exploring its effectiveness, safety, and potential applications. These studies have investigated different formulations, dosages, and uses of bupropion, ranging from its role in treating major depressive disorder to its potential in weight management after bariatric surgery. The trials have provided valuable insights into the drug’s pharmacokinetics, efficacy, and safety profile in diverse patient populations.

Table of Contents

What is Bupropion Hydrochloride?

Bupropion hydrochloride is a prescription medication used to treat several conditions, primarily depression. It’s known by various brand names, including Wellbutrin, Zyban, and Contrave[1]. Bupropion comes in different formulations, such as immediate release (IR), sustained release (SR), and extended release (XL) tablets[2].

Uses of Bupropion Hydrochloride

Bupropion is approved for several uses:

  • Major Depressive Disorder (MDD): Bupropion is primarily used to treat depression[2]. It can help improve mood, energy levels, and overall well-being in people with depression.
  • Smoking Cessation: Under the brand name Zyban, bupropion is used to help people quit smoking[3]. It can reduce cravings and withdrawal symptoms associated with quitting tobacco.
  • Attention Deficit Hyperactivity Disorder (ADHD): Some studies have explored the use of bupropion in treating ADHD, particularly in adults[4].
  • Weight Management: When combined with naltrexone (as in the medication Contrave), bupropion may be used to help with weight loss in certain individuals[5].
  • Seasonal Affective Disorder (SAD): Bupropion XL is approved for preventing episodes of SAD, a type of depression that occurs at certain times of the year, usually in winter.

How Bupropion Works

Bupropion is classified as an atypical antidepressant. It works differently from many other antidepressants:

  • It affects brain chemicals called neurotransmitters, particularly norepinephrine and dopamine.
  • By increasing the levels of these neurotransmitters, bupropion can help improve mood, increase energy, and reduce cravings for tobacco or food.
  • Unlike many antidepressants, bupropion doesn’t significantly affect serotonin levels, which may result in fewer sexual side effects compared to other antidepressants[6].

Dosage and Administration

Bupropion dosage varies depending on the condition being treated and the formulation used. Here are some general guidelines:

  • For depression, a common starting dose is 150 mg once daily, which may be increased to 300 mg daily[2].
  • For smoking cessation, treatment often starts 1-2 weeks before the planned quit date, usually at 150 mg once daily for the first three days, then 150 mg twice daily[3].
  • Extended-release formulations are typically taken once daily in the morning[2].
  • It’s important to follow your doctor’s instructions carefully and not to adjust your dose without consulting your healthcare provider.

Potential Side Effects

Like all medications, bupropion can cause side effects. Common side effects may include:

  • Dry mouth
  • Nausea
  • Insomnia or sleep disturbances
  • Agitation or anxiety
  • Headache
  • Constipation
  • Changes in appetite
  • Increased sweating

In rare cases, bupropion may increase the risk of seizures. It’s important to discuss all potential risks and side effects with your healthcare provider[2].

Ongoing Research

Researchers continue to study bupropion for various uses:

  • Binge Eating Disorder: Studies are investigating the combination of bupropion and naltrexone for treating binge eating disorder, with or without obesity[1].
  • Sexual Function: Some research is exploring whether bupropion can help improve sexual desire in women with breast or gynecologic cancer[6].
  • Weight Management After Bariatric Surgery: Researchers are studying whether bupropion, combined with naltrexone, can help manage weight regain in people who have had bariatric surgery[5].
  • ADHD in Methadone Patients: Studies are investigating the use of bupropion to treat ADHD in adults receiving methadone treatment for opioid addiction[4].

It’s important to note that these are areas of ongoing research, and bupropion may not be approved for these uses. Always consult with a healthcare professional about the most appropriate treatments for your specific situation.

Aspect Details
Conditions Studied Major Depressive Disorder, Smoking Cessation, Weight Management post-bariatric surgery
Formulations Extended-release (XL), Modified-release (MR), Immediate-release (IR)
Dosages 150 mg, 300 mg, 450 mg daily
Study Designs Randomized controlled trials, Open-label studies, Pharmacokinetic studies
Primary Outcomes Pharmacokinetic parameters, Efficacy in smoking cessation, Weight loss
Safety Assessments Adverse events, Vital signs, Laboratory parameters
Study Durations Ranging from a few weeks to several months with long-term follow-ups
Special Populations Chinese subjects, Post-bariatric surgery patients

FAQ

  • What conditions is Bupropion Hydrochloride being studied for in these clinical trials? Bupropion Hydrochloride is being studied for various conditions including major depressive disorder, smoking cessation, and weight management in patients who have undergone bariatric surgery.
  • What are the different formulations of Bupropion Hydrochloride mentioned in the trials? The trials mention several formulations of Bupropion Hydrochloride, including extended-release tablets (XL), modified-release tablets (MR), and immediate-release (IR) formulations. Some specific brand names mentioned are Wellbutrin XL, Budeprion XL, and Zyban.
  • What dosages of Bupropion Hydrochloride are being studied? The studies investigate various dosages, including 150 mg, 300 mg, and 450 mg daily doses. Some trials compare different dosages to determine the most effective and safe dose for specific conditions.
  • How long do these clinical trials typically last? The duration of the trials varies. Some pharmacokinetic studies last for a few weeks, while others, especially those investigating efficacy in conditions like smoking cessation, can last several months, with follow-ups extending up to 26 weeks or more.
  • What are some of the main outcomes being measured in these trials? The trials measure various outcomes depending on their focus. These include pharmacokinetic parameters (like maximum concentration and time to reach peak plasma concentration), efficacy measures (such as smoking abstinence rates or changes in body weight), and safety assessments (including adverse events, changes in vital signs, and laboratory parameters).

Ongoing Clinical Trials on Bupropion Hydrochloride

  • Study on the Effects of Escitalopram and Bupropion on Dopamine Levels in Patients with Major Depression

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria

  • Study on the Effect of Citalopram, Sertraline, and Lithium for Patients with Bipolar Depression After First-Line Treatment Failure

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Germany Greece Italy Spain

  • Study on the Effect of Ketamine and Esketamine in Patients with Major Depressive Disorder After First-Line Treatment Failure

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Germany Greece Italy Spain

  • Randomized trial of bupropion hydrochloride for fatigue in patients with long COVID (post‑COVID syndrome)

    Not yet recruiting

    1 1
    Investigated drugs:
    Germany

  • Testing a Pharmacogenetic-Guided Treatment Selection Strategy with Antidepressant Drug Combination for Patients with Depressive Disorder

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • Study on Bupropion Hydrochloride and Naltrexone Hydrochloride for Patients with Weight Regain After Bariatric Surgery

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Effects of a Mediterranean Diet with Intermittent Fasting vs. Bupropion and Naltrexone in Overweight Patients with Type 2 Diabetes and Liver Fibrosis

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Enhanced Treatment for Schizophrenia, Depression, and Bipolar Disorder Using Esketamine, Bupropion, and Quetiapine for Patients with Initial Treatment Failure

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany Italy Spain

Glossary

  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Bioavailability: The proportion of a drug that enters the circulation when introduced into the body and so is able to have an active effect.
  • Extended-release (XL): A formulation of a drug designed to release the active ingredient slowly over time, allowing for less frequent dosing.
  • Placebo: An inactive substance or treatment used in clinical trials as a control to compare with the active drug being tested.
  • Randomized controlled trial: A type of scientific experiment where participants are randomly assigned to different treatment groups to compare outcomes.
  • Adverse event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Steady-state concentration: The situation where the overall intake of a drug is in dynamic equilibrium with its elimination.
  • Point Prevalence Abstinence (PPA): A measure of smoking cessation success, typically defined as not smoking for a specified period (e.g., 7 days) prior to a follow-up assessment.
  • Titration: The process of gradually adjusting the dose of a medication to achieve the optimal therapeutic effect with minimal side effects.
  • Bioequivalence: The property wherein two drugs with identical active ingredients or two different dosage forms of the same drug possess similar bioavailability and produce the same effect at the site of physiological activity.

References

  1. https://clinicaltrials.gov/study/NCT03539900
  2. https://clinicaltrials.gov/study/NCT02698553
  3. https://clinicaltrials.gov/study/NCT01015170
  4. https://clinicaltrials.gov/study/NCT00061087
  5. https://clinicaltrials.gov/study/NCT02616315
  6. https://clinicaltrials.gov/study/NCT03180294